openPR Logo
Press release

CV Sciences, Inc. (OTC: CVSI) Investor Alert: Update in Lawsuit against . CV Sciences, Inc

03-06-2020 06:06 PM CET | Politics, Law & Society

Press release from: Shareholders Foundation

A lawsuit is pending for certain investors in CV Sciences, Inc. (OTC: CVSI) shares.

A lawsuit is pending for certain investors in CV Sciences, Inc. (OTC: CVSI) shares.

The Shareholders Foundation announced that a lawsuit is pending for certain investors in shares of CV Sciences, Inc. (OTC: CVSI).

Investors who purchased shares of CV Sciences, Inc. (OTC: CVSI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On August 24, 2018, a lawsuit was filed against CV Sciences, Inc. (OTC: CVSI) over alleged violations of Federal Securities Laws. The plaintiff claims that between June 19, 2017 and August 20, 2018, the Defendants failed to disclose that its Patent #15/426,617 received a non-final rejection from the USPTO on April 27, 2017, that a final rejection from the USPTO on December 14, 2017, and that as a result of the foregoing, Defendants' statements about CV Sciences' business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Those who purchased shares of CV Sciences, Inc. (OTC: CVSI) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CV Sciences, Inc. (OTC: CVSI) Investor Alert: Update in Lawsuit against . CV Sciences, Inc here

News-ID: 1957972 • Views: 519

More Releases from Shareholders Foundation

Lawsuit filed for Investors in shares of TiVo Corporation (NASDAQ: TIVO) in conn …
The Shareholders Foundation announced that an investor, who currently hold shares of TiVo Corporation (NASDAQ: TIVO), filed a lawsuit in connection with the takeover of TiVo Corporation. Investors who purchased shares of TiVo Corporation (NASDAQ: TIVO) and currently hold any of those NASDAQ: TIVO shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. San Jose, CA based TiVo Corporation provides media and entertainment
Investigation for Investors of SB One Bancorp (NASDAQ: SBBX) announced in connec …
An investigation was announced concerning whether the takeover of SB One Bancorp is unfair to NASDAQ: SBBX stockholders. Investors who purchased shares of SB One Bancorp (NASDAQ: SBBX) and currently hold any of those NASDAQ: SBBX shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of SB One Bancorp breached
Investgiation for Long-Term NASDAQ: KINS Investors announced over possible Wrong …
An investigation on behalf of current long-term investors in shares of Kingstone Companies, Inc. (NASDAQ: KINS) was announced over potential breaches of fiduciary duties by certain officers and directors at Kingstone Companies, Inc. Investors who purchased shares of Kingstone Companies, Inc. (NASDAQ: KINS) and currently hold any of those Kingstone Companies, Inc. (NASDAQ: KINS shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation for NYSE:FCAU Investors announced over possible Wrongdoing at Fiat …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Fiat Chrysler Automobiles N.V.. Investors who are current long term investors in Fiat Chrysler Automobiles N.V. (NYSE: FCAU) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: FCAU stocks follows a lawsuit filed against Fiat

All 5 Releases


More Releases for Sciences

Conference on Nutrition and Food Sciences
ConferenceSeries LLC Ltd is overwhelmed to announce the commencement of the 22nd World Congress on Nutrition & Food Sciences, which is to be held during June 17-18, 2019 in Brisbane, Australia. This Nutrition assembly point awesomely emphasis on Nutrition & Food Sciences - Fundamentals of a Healthy Life. Contact: nutritionasia@nutritionalconference.com Conference Series LLC LTD is an open resource platform that conducts 3000+ global events including International Conferences, Workshops, Symposia, Trade Shows, Exhibitions and
BOC Sciences Launched Impurities for Scientific Research
BOC Sciences, headquartered in Shirley, New York, announced that a rich collection of impurities are now available for scientific research use on July 27, 2018. In the process of drug development and manufacturing, profiling and controlling impurities level is of considerable importance as their side pharmaceutical effects may affect the efficacy and safety of active pharmaceutical ingredients (APIs). In most cases, an exceeding amount of impurity level would lead
Bayer Crop Sciences Ltd
Bayer Crop Sciences Ltd Bayer Crop Sciences Ltd- Company Profile & Financial Analysis” contains in depth information and data about the company and its operations. You will find information on the business structure, areas of operation, products and services offered by the company. It also comprises SWOT analysis, key ratios, historical financial data and insider’s view on financial stability and industrial ranking with financial forecasts for two- year period. This report is
Gallene Sciences, promoting health and well-being.
Gallene Sciences’ strategy emphasises three key areas: -Health: Gallene science manufactures and distributes affordable high- quality generic medicines, complying with regulatory standards for manufacturing, health and safety. Through its range of pharma- ceuticals, Gallene Sciences laboratory treats a wide number [well known] viruses and chronic It lends its expertise to providing high- quality but affordable therapies for HIV / AIDS. It also contributes to the treatment of viral hepatitis, diabetes or and hypertension. Research: Gallene Sciences’ research center
Global Life Sciences BPO Market
The Global Life Sciences BPO Market was valued US$ 180.4 billion in 2015 and is projected to reach US$ 505.0 billion by 2024, according to a new report published by Coherent Market Insights.Reducing cost and increasing focus on core strengths is influencing medical device and pharmaceutical companies to outsource their processes to contract manufacturing organizations (CMO) and contract research organizations (CRO). Request Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/24 Increasing demand for low cost
Global life sciences BPO market
TheGlobal life sciences BPO market was valued US$ 180.4 billion in 2015 and is projected to reach US$ 505.0 billion by 2024, according to a new report published by Coherent Market Insights.Reducing cost and increasing focus on core strengths is influencing medical device and pharmaceutical companies to outsource their processes to contract manufacturing organizations (CMO) and contract research organizations (CRO). Request Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/24 Increasing demand for low cost drugs,